

Jefferies London 2026: Forbion, the most active lead investor in private biotech financing rounds globally last year, raised €2.3 billion across two new funds last month
Co-Owner and Managing Partner Sander Slootweg discusses the new funds and what kind of companies the funds might be deployed towards. He also shares his ideas and recommendations on how to make Europe more competitive in life sciences and keep companies in the region, and gives his take on the sector's outlook in 2027. Coverage brought to you by
3 days ago


Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run. Coverage brought to you by
4 days ago


HLTH USA 2026: Abbott's Chief Medical Officer for Multi-Cancer Detection describes the science behind multi-cancer early detection tests and shares his thoughts on where the field is headed
Tom Beer describes the idea behind these blood tests that interrogate biomarkers that are derived from many types of cancers.
5 days ago


Jefferies London 2026: Sofinnova Partners announced today a new $815M fund today that will invest in mostly later stage European companies
Managing Partner Graziano Seghezzi tells us about the new fund and what it will invest in, and comments on the environment for European biotech today. Coverage brought to you by
5 days ago


Mizuho Senior Biotech Analyst Graig Suvannavejh gives his take on biotech's pause and discusses companies he covers with key items in the news
He discusses Belite Bio, Tarsus, Alkermes, Palvella, Corvus, and more. Chapters General sentiment - 1:35 Belite Bio - 2:48 Tarsus - 5:50 Alkermes - 8:25 Palvella - 12:08 Corvus - 14:35
Nov 12


Stifel's Tim Opler on the state of biotech
Ahead of a 100+ slide "State of Biotech" report he is publishing tomorrow, he discusses the impact of Washington on biotech, how the sector has been trading lately, China, M&A and a lot more Coverage brought to you by
Nov 11


Stifel's Head of Global Equity Capital Markets Seth Rubin shares his take on the state of biotech and the current environment for companies to raise money
He says that markets have taken a pause but he believes they are healthy and not broken, and he is optimistic about the future. Coverage brought to you by
Nov 11


Stifel Research Analyst Alex Thompson shares his take on the state of the I&I space and highlights a few key companies
He discusses Kymera, Roivant, and Oruka. Chapters General take on I&I - 0:44 Kymera - 2:45 Roivant - 4:50 Oruka - 7:00 Coverage brought to you by
Nov 10


BIO-Europe 2026: KHAN, an early-stage investor based in Germany, works with academics to progress research projects, many of which turn into companies
Managing Partner Michael Hamacher tells us how it has connections to Max Planck and other European academic institutions. He also shares his thoughts on how companies should protect their ideas and IP. Coverage brought to you by
Nov 10


Stifel's Head of Therapeutics Research Paul Matteis shares his take on biotech and discusses companies he covers that have been in the news
He discusses Biogen, Alnylam, Xenon, and Compass Pathways Chapters General sentiment - 0:25 Biogen - 2:00 Alnylam - 4:14 Xenon - 6:44 Compass Pathways - 8:23 Coverage brought to you by
Nov 10


BIO-Europe 2026: Andera Partners' Olivier Litzka discusses his firm's approach to venture, and the idea behind the European Life Sciences Coalition
He says that it is important for investors and companies to partner together to competing globally with the U.S. and China, and he advocates strongly for a pan-European stock exchange that can help raise larger amounts of capital for local companies. Coverage brought to you by
Nov 9


BIO-Europe 2026: Biotech veteran Dr. Jeremy Levin discusses a new era in neuroscience and his opinion of the best way to go about drug development in this key field
Currently the Executive Chair of Ovid Therapeutics, he discusses the key to doing neuroscience right today and also the importance of having the right investors in your corner. Coverage brought to you by
Nov 9


From Montreal: A panel of top venture investors who are based in Montreal discuss the state of biotech in the area and across Canada
Sofinnova Investments' Maha Katabi, Finchley Healthcare Ventures' Pierre Beauparlant, and Amplitude Ventures' Jean-Francois Pariseau describe the biotech scene here, what Montreal and other Canadian biotech hubs do well, what could be improved, and the environment for entrepreneurs to turn ideas into companies.
Nov 4


Mizuho Senior Biotech Analyst Salim Syed shares his take on biotech's current lull, and discusses companies he covers
He comments on Arcus, Vaxcyte, Cytokinetics, BridgeBio, Maze Therapeutics, and Century Therapeutics. Chapters General sentiment - 1:37 Arcus - 3:49 Vaxcyte - 6:40 Cytokinetics - 10:30 BridgeBio - 14:48 Maze Therapeutics - 17:40 Century Therapeutics - 19:47
Oct 21


Barclays Biotech Analyst Ellie Merle previews this weekend's highly anticipated cancer vaccine data from Merck and Moderna at ESMO
She says that consensus is a hazard ratio of 0.6 and that degrees of success could be viewed whether the data comes in lower or higher than that.
Oct 21







.png)
